2023; Hasmann and Schemainda 2003), in blocking sEV‐NAMPT as a treatment option in various animal models. In addition, FK866 inhibited the sEV‐NAMPT‐SLC27A4 pathway because a reduced TG concentration was observed in the treatment group. These findings suggest the possibility of targeting sEV‐NAMPT as a promising therapeutic strategy for HCC patients. Although FK866 had a positive outcome in our study, we are aware that phase II clinical trials of cutaneous T‐cell lymphoma have failed because of its high toxicity (Wei and Zhang 2022). Here, NAMPT is linked to hepatocellular carcinoma.